Table 2. Characteristics of Sample B (all and by 10% weight gain one year after transplantation).
| Characteristic | All | wg≥10%* | wg<10%* | p-value # |
|---|---|---|---|---|
| 156 | 42 | 78 | ||
| Recipient age at transplantation (years), median (range) | 48 (22–68) | 47 (26–66) | 49 (22–68) | 0.4 |
| Recipient men (%) | 60.9 | 59.5 | 61.5 | 0.8 |
| Period of follow up (months), median (range) | 12 (1–60) | 12 (1–60) | 12 (1–60) | 1 |
| Living donor (%) | 11.5 | 11.9 | 7.7 | 0.4 |
| Donor age (years), median (range) | 43.5 (10–73) | 45 (10–65) | 43 (11–69) | 0.7 |
| Transplanted organ (%) | ||||
| kidney | 65.4 | 76.2 | 60.3 | 0.03 |
| Liver | 23.7 | 7.1 | 26.9 | |
| Lung | 10.9 | 16.7 | 12.8 | |
| Before transplant | ||||
| BMI (kg/m2), median (range) | 23.4 (15.8–37.3) | 22.9 (18.7–33.5) | 24.2 (15.8–37.3) | 0.06 |
| Overweight (25 kg/m2 ≤ BMI >30 kg/m2), % | 24.1 | 14.3 | 30.8 | 0.08 |
| Obese (BMI ≥ 30 kg/m2), % | 10.9 | 9.5 | 12.8 | |
| At 12 months after transplant | ||||
| BMI (kg/m2), median (range) | 25.2 (16.5–39.3) | 26.8 (20.9–39.3) | 24.3 (16.5–35.4) | 0.0006 |
| Overweight (25 kg/m2 ≤ BMI >30 kg/m2), % | 35.1 | 45.2 | 28.2 | 0.004 |
| Obese (BMI ≥ 30 kg/m2), % | 18.5 | 28.6 | 14.1 | |
| Incidence of NODAT (%) | 28.8 | 30.9 | 35.9 | 0.6 |
| CMV serostatus (%) | ||||
| Recipient CMV infection (R+) | 49.3 | 30.8 | 36.1 | 0.6 |
| Donor CMV infection (D+) | 61.5 | 23.1 | 15.3 | |
| Recipient and Donor CMV infection (R+D+) | 27.6 | 30.8 | 27.8 | |
| Calcineurin inhibitors (%) | ||||
| TAC | 34.6 | 26.2 | 47.4 | 0.02 |
| CSA | 65.4 | 73.8 | 52.7 |
wg: weight gain, CMV: Cytomegalovirus, TAC: Tacrolimus, CSA: Cyclosporine, NODAT: New Onset Diabetes After Transplant.
# comparison between wg≥10% and wg<10%
*at 12 months after transplantation, missing n = 36